Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCLVSF 85 5-Year Yield-on-Cost % is 2.12 as of Jul. 17, 2026, which is 128% above its 10-year median of 0.93. GuruFocus rates CLVSF with a GF Score™ of 85/100 and a GF Value™ of $21.63 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 325 Medical Devices & Instruments companies, CellaVision AB ranks worse than 53.54% on this metric.
CellaVision AB's yield on cost for the quarter that ended in Mar. 2026 was 2.12.
The historical rank and industry rank for CellaVision AB's 5-Year Yield-on-Cost % or its related term are showing as below:
CLVSF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.16 Med: 0.93 Max: 2.12
Current: 2.12
During the past 13 years, CellaVision AB's highest Yield on Cost was 2.12. The lowest was 0.16. And the median was 0.93.
CLVSF's 5-Year Yield-on-Cost % is ranked worse than 53.54% of 325
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs CLVSF: 2.12
CellaVision AB (OTCPK:CLVSF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CellaVision AB 5-Year Yield-on-Cost % Related Terms
CLVSF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, CellaVision AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of CellaVision AB is calculated as
CellaVision AB (CLVSF) has a 5-Year Yield-on-Cost % of 2.12 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellaVision AB and its competitors. This is 128% above median its historical median of 0.93. Over the past decade, CellaVision AB's 5-Year Yield-on-Cost % has ranged from 0.16 to 2.12. According to the industry distribution chart, CellaVision AB ranks #174 out of 325 companies in the Medical Devices & Instruments industry, placing it in the top 53.5%.
Is CellaVision AB's 5-Year Yield-on-Cost % too high?
CellaVision AB's current 5-Year Yield-on-Cost % of 2.12 is 128% above median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 2.12. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.34. CellaVision AB's value of 2.12 is 9.4% below this industry median. Based on the distribution chart, CellaVision AB ranks #174 out of 325 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #174 out of 325 companies for 5-Year Yield-on-Cost %. This places CellaVision AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. CellaVision AB's value of 2.12 is 9.4% below this benchmark. Historically, CellaVision AB's own 5-Year Yield-on-Cost % has ranged from 0.16 to 2.12 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 2.34, CellaVision AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current 5-Year Yield-on-Cost % of 2.12 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current 5-Year Yield-on-Cost % is 2.12, which is 128% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CLVSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $21.63, compared to a current price of $14.00 — trading 35.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.12, which is 128% above median its 10-year median of 0.93 and 9.4% below the Medical Devices & Instruments industry median of 2.34. CellaVision AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CellaVision AB (CLVSF), the current 5-Year Yield-on-Cost % is 2.12 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CLVSF) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $14.00 is trading 35.3% below its estimated GF Value™ of $21.63.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CLVSF:
5-Year Yield-on-Cost %: 2.12 (128% above median its 10-year median of 0.93)
GF Value™: $21.63 vs. price of $14.00 (35.3% below fair value)
Industry Position: 9.4% below the Medical Devices & Instruments median (#174 of 325)
No single metric tells the full story. See the CLVSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
85GF Score
Get the complete analysis for CLVSF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVSF has been successfully added to your 
